The Inflation Reduction Act & Medicare Pricing for Drugs and Biologics

Join us for a webinar led by Matt Wetzel, a partner on our Life Sciences Regulatory team at Goodwin, for an overview of recent sweeping changes to how the government intends to pay for pharmaceuticals and biologics under the Inflation Reduction Act of 2022. The new Medicare price negotiation program, inflation-based rebates, and other changes to how Medicare covers and pays for drugs will have an impact for many years to come. Matt will provide an analysis of the Inflation Reduction Act’s requirements as well as discuss how drug companies are currently reacting, and what they can do to prepare for the Inflation Reduction Act’s full implementation.